ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Changes In Clinical Trials Mechanism Inevitable, But NCI Says It will Heed Critics Of Proposals

April 18, 1986

FDA News: FDA Approves Reagent System for Graft-Versus-Host Disease

January 24, 2014

Report on Carcinogens: Advisors Recommend Tobacco, UV Light, Tamoxifen, For Report

November 7, 1997

Home Test Detects Hematuria Earlier

August 4, 1989

Two Workshops To Look For New Research Areas

October 29, 1976

Philadelphia Group Begins BMT Trial for Breast Cancer

April 5, 1991